raf-A Activators
RAF-A Activators encompass a range of chemical compounds that indirectly enhance the functional activity of RAF-A through modulation of various signaling pathways, particularly the MAPK/ERK pathway. Sorafenib, Vemurafenib, Dabrafenib, and GDC-0879 are kinase inhibitors primarily targeting BRAF kinases. Their inhibitory action on BRAF, especially in the context of mutated forms like BRAF V600E, leads to a compensatory increase in RAF-A activity to maintain signaling homeostasis. This is crucial as RAF-A plays a significant role in cell proliferation and survival pathways. Similarly, LY3009120 and PLX8394, while being pan-RAF and BRAF inhibitors respectively, paradoxically lead to RAF-A activation in specific cellular contexts where RAF/MEK/ERK signaling is dysregulated. This paradoxical activation illustrates the intricate regulatory mechanisms that cells employ to balance signaling networks.
In addition to BRAF inhibitors, a significant contribution to RAF-A activation comes from MEK inhibitors like Trametinib, Cobimetinib, Selumetinib (AZD6244), U0126, and PD 0325901. These compounds target MEK1/2, leading to a reduction in ERK signaling downstream of RAF kinases. As a result, a feedback loop is initiated, resulting in the upregulation or enhanced activation of RAF-A. This compensatory mechanism is an adaptive response of the cell to maintain essential signaling pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, including RAF kinases. By inhibiting other kinases, Sorafenib leads to a compensatory increase in RAF-A signaling as a feedback mechanism. This enhances RAF-A-mediated MAPK/ERK pathway activation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib, designed to inhibit BRAF V600E mutations, can paradoxically activate RAF-A in cells with wild-type BRAF. This occurs through transactivation of RAF-A, enhancing its kinase activity and downstream signaling. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib, a BRAF inhibitor, can lead to RAF-A activation in cells with wild-type BRAF. It induces RAF-A dimerization and activation, promoting MAPK/ERK signaling. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib, an EGFR inhibitor, can indirectly activate RAF-A through a feedback loop. Inhibition of EGFR leads to compensatory signaling changes that enhance RAF-A activity as part of the MAPK/ERK pathway. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual inhibitor of EGFR and HER2, can indirectly lead to RAF-A activation. By inhibiting upstream tyrosine kinases, it causes compensatory changes that enhance RAF-A's role in cell signaling. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor. By inhibiting downstream of RAF-A, it can lead to a feedback increase in RAF-A activity as the cell attempts to overcome the blockade of the MAPK/ERK pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, another MEK inhibitor, similarly to Selumetinib, can indirectly enhance RAF-A activity through feedback mechanisms that try to compensate for the inhibition of the MAPK/ERK pathway. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib, a MEK inhibitor, can indirectly activate RAF-A. The inhibition of MEK leads to feedback loops that upregulate RAF-A activity, as the cell attempts to maintain MAPK/ERK pathway signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, primarily a receptor tyrosine kinase inhibitor, can indirectly enhance RAF-A activity. Its inhibition of multiple kinases can result in compensatory cellular responses that activate RAF-A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an inhibitor of MEK, can indirectly lead to increased RAF-A activity. This is due to feedback mechanisms within the MAPK/ERK pathway aiming to compensate for the reduced pathway signaling. | ||||||